Merck hits fresh 52-week high, levels to watch The shares are up over 3.3% to $53.75, a new 52-week high. At that price, next resistance is at $55.14. Support is at the prior 52-week high at $53.44, which was also a recent pivot high. Morgan Stanley earlier upgraded the shares to Overweight. The firm's price target is $60.
News For MRK From The Last 14 Days
Check below for free stories on MRK the last two weeks.
FDA approves Belsomra sleep drug The Food and Drug Administration approved Belsomra tablets for use as needed to treat difficulty in falling and staying asleep. Belsomra is an orexin receptor antagonist and is the first approved drug of this type. Belsomra will be dispensed with an FDA-approved patient Medication Guide that provides instructions for its use and important safety information. Belsomra is a controlled substance because it can be abused or lead to dependence. Belsomra is made by Merck, Sharpe & Dohme.